Solventum Co. (NYSE:SOLV) Shares Bought by Clifford Capital Partners LLC

Clifford Capital Partners LLC raised its holdings in Solventum Co. (NYSE:SOLV) by 22.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 279,479 shares of the company’s stock after purchasing an additional 51,533 shares during the period. Solventum accounts for approximately 3.9% of Clifford Capital Partners LLC’s portfolio, making the stock its 5th largest holding. Clifford Capital Partners LLC’s holdings in Solventum were worth $19,485,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Solventum by 4.2% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock worth $346,000 after purchasing an additional 200 shares during the last quarter. National Bank of Canada FI raised its holdings in Solventum by 4.0% in the 2nd quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock valued at $314,000 after acquiring an additional 236 shares during the last quarter. IVC Wealth Advisors LLC lifted its stake in shares of Solventum by 5.0% during the 3rd quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock worth $464,000 after purchasing an additional 318 shares during the period. KKM Financial LLC boosted its holdings in shares of Solventum by 7.9% during the third quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock worth $304,000 after purchasing an additional 319 shares during the last quarter. Finally, Copeland Capital Management LLC acquired a new stake in shares of Solventum during the third quarter worth $26,000.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. The Goldman Sachs Group increased their target price on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research report on Monday, August 12th. Stifel Nicolaus initiated coverage on shares of Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. Piper Sandler upped their price target on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. BTIG Research initiated coverage on shares of Solventum in a report on Thursday, September 5th. They issued a “neutral” rating on the stock. Finally, Wells Fargo & Company dropped their price objective on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Solventum currently has an average rating of “Hold” and a consensus target price of $68.00.

Solventum Price Performance

Shares of SOLV stock opened at $71.50 on Wednesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The firm has a fifty day simple moving average of $70.51 and a 200-day simple moving average of $62.40. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.